None
Conditions
Interventions
Treatment Group 1 :Selenium 200ug (1 tab) daily
Treatment Group 2:Atorvastatin 20mg (1 tab) daily
Treatment Group 3:Doxycycline 50mg (1 tab) daily
Treatment Group 4:Hydroxychloroquine 200mg (1 tab) daily
Treatment Group 5:Vitamin D 2800 IU (1 tab) daily
Control Group:Placebo (1 tab) daily
Sponsors
The Chinese University of Hong Kong
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. TED with mild severity (at least 1 sign) as defined by EUGOGO in the most affected eye: (1) Mild lid retraction of either upper or lower eyelid (marginal reflex distance 1 or 2 between 5 to 7mm) (2) Mild soft-tissue involvement (NOSPECS class 2a and 2b) (3) Exophthalmos 3/7
Exclusion criteria
Exclusion criteria: 1. Age 80 yrs. 2. Compressive optic neuropathy by EUGOGO criteria 3. Exophthalmos>22mm 4. Diplopia in primary or reading position, and/ or ocular torticollis 5. Monocular duction in any direction of 3 times the upper normal range. 19. Severe familial hyperlipidaemia or presence of more than one associated cardiovascular risk factor (diabetes, high blood pressure, smoking, familial history of acute cardiovascular events, obesity), medically indicated for cholesterol-lowering medications.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion achieving excellent-to-good versus similar-or-worse CTS at month 6 (response) and 12 (recurrence).; | — |
Secondary
| Measure | Time frame |
|---|---|
| Serial comparisons of CTS, orbital, psychosocial, serological parameters among groups;Proportion of patients requiring additional treatments for TED;Complications;Therapeutic responses;Factors associated with compliance; | — |
Countries
China
Contacts
Public ContactKam Lung Chong
The Chinese University of Hong Kong
Outcome results
None listed